New Japan research scandal brewing over Alzheimer's study

Japan's health ministry said Friday it was probing claims falsified data was used in an Alzheimer's disease study involving major pharmaceutical firms, a day after filing an unrelated criminal complaint against Swiss drugs giant Novartis.

Health officials said they were questioning researchers after being told false data was used in clinical testing for the $28 million government-backed Alzheimer's study, aimed at improving diagnosis of the disease.

The research involved 11 drugs firms, including Pfizer and Bristol-Myers Squibb and Japanese giants Takeda Pharmaceutical and Astellas Pharma, medical imaging companies and nearly 40 hospitals and medical organisations. The public and privately-financed study, dubbed J-ADNI, began in 2007.

The allegations came to light just a day after Japanese officials slapped Novartis with a criminal complaint which alleged its local unit exaggerated advertising for popular blood-pressure Diovan.

A former Tokyo University professor and project researcher on the Alzheimer's study reported the false data claims to . Novartis was not involved in the study.

"After verifying the facts about these allegations, we will deal with the issue appropriately, setting up an investigation team if necessary," a official told AFP.

Health Minister Norihisa Tamura told reporters in Tokyo Friday that the probe would get to the bottom of whether the data was made up and, if so, how it made its way into the high-profile study.

"If there really has been data falsification, that would be a grave problem, so we are investigating carefully," he said.

A report in the Asahi Shimbun Friday said the newspaper had obtained internal documents highlighting at least four instances where researchers linked to the drugs makers and medical institutions tried to falsify data.

In response, a Pfizer spokesman in Japan said the drugs giant supplied some financing for the research, but did not employ any researchers.

Others firms could not immediately be reached for comment.

Health officials lodged the unrelated claims against Novartis months after a university said data in clinical studies might have been skewed to falsely promote Diovan, which is also known as Valsartan, in the prevention of stroke and angina.

There is no suggestion that Diovan is ineffective in combating blood pressure problems.

add to favorites email to friend print save as pdf

Related Stories

Japan files criminal complaint against Novartis arm

Jan 09, 2014

Japan's health ministry on Thursday filed a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, the company said.

Japan to file criminal complaint against Novartis (Update)

Jan 07, 2014

Japan's health ministry plans to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, an official said Wednesday.

Japan to seek criminal prosecution of Novartis

Dec 18, 2013

Japan's health ministry intends to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged fabrication of drugs data, a report said Wednesday.

Recommended for you

Cold sores increase the risk of dementia

5 hours ago

Infection with herpes simplex virus increases the risk of Alzheimer's disease. Researchers at Umeå University, Sweden, claim this in two studies in the journal Alzheimer's & Dementia.

World first effort to prevent dementia in high-risk people

Oct 15, 2014

Dementia will soon engulf more than 100 million people across the globe, but an international research group is leading a world-first effort to prevent dementia in people who are at high risk of this insidious disease.

Aluminium and its likely contribution to Alzheimer's disease

Oct 13, 2014

A world authority on the link between human exposure to aluminium in everyday life and its likely contribution to Alzheimer's disease, Professor Christopher Exley of Keele University, UK, says in a new report that it may ...

User comments